Gard Aasmund Skulstad Johanson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gard Aasmund Skulstad Johanson has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Charalampos Tzoulis
Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway
2 shared publications - Christian Dölle
Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway
1 shared publication - Erika Fernandez-Vizarra
Department of Biomedical Sciences, University of Padova, Padova, Italy
1 shared publication - Erika Sheard
Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway
1 shared publication Fiona Dick
Neuro‐SysMed Center Department of Neurology Haukeland University Hospital Bergen Norway
1 shared publicationGeir Olve Skeie
Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway
1 shared publication
Latest Publications
- Open Access
- 14 August 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (7) , 1218-1228
Platelet mitochondrial complex I and IV activities are not reliable stratification biomarkers in Parkinson's disease
Background: Mitochondrial dysfunction, particularly complex I (CI) deficiency, is considered an integral feature of Parkinson's disease (PD). However, recent findings indicate that widespread neuronal CI deficiency in the brain is only present in a subpopulation of 20–30% of cases. This stratification may be relevant for selecting participants for clinical trials, emphasizing the need for clinically applicable biomarkers. We previously reported CI deficiency in skeletal muscle biopsies of a subpopulation of persons with PD (PwPs), suggesting potential for mitochondrial stratification using extra-neural tissues. Platelets are another tissue previously reported to exhibit mitochondrial respiratory defects in PD. However, studies have generally involved small sample sizes and reported variable results. Objective: To determine whether platelets exhibit impaired mitochondrial respiratory chain complex activity in PwPs, or in a subpopulation of PwPs. Methods: Using spectrophotometric activity assays, we assessed CI and complex IV (CIV) activities in platelet samples from 61 PwPs and 31 neurologically healthy controls from a well-characterized prospective cohort. The correlation between activities measured in platelets and skeletal muscle was also explored in 51 of the same individuals. Results: Platelet CI and CIV activities showed no difference between PwPs and controls at the group level, nor evidence of a subgroup with deficiency of either complex. There was no correlation between complex activities in platelet samples and skeletal muscle biopsies from the same individuals. Conclusions: Based on these results, we propose that platelet CI or CIV activities are not sensitive markers of mitochondrial dysfunction in PD.
- 14 August 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (7) , 1218-1228
Open AccessPlatelet mitochondrial complex I and IV activities are not reliable stratification biomarkers in Parkinson's disease
Background: Mitochondrial dysfunction, particularly complex I (CI) deficiency, is considered an integral feature of Parkinson's disease (PD). However, recent findings indicate that widespread neuronal CI deficiency in the brain is only present in a subpopulation of 20–30% of cases. This stratification may be relevant for selecting participants for clinical trials, emphasizing the need for clinically applicable biomarkers. We previously reported CI deficiency in skeletal muscle biopsies of a subpopulation of persons with PD (PwPs), suggesting potential for mitochondrial stratification using extra-neural tissues. Platelets are another tissue previously reported to exhibit mitochondrial respiratory defects in PD. However, studies have generally involved small sample sizes and reported variable results. Objective: To determine whether platelets exhibit impaired mitochondrial respiratory chain complex activity in PwPs, or in a subpopulation of PwPs. Methods: Using spectrophotometric activity assays, we assessed CI and complex IV (CIV) activities in platelet samples from 61 PwPs and 31 neurologically healthy controls from a well-characterized prospective cohort. The correlation between activities measured in platelets and skeletal muscle was also explored in 51 of the same individuals. Results: Platelet CI and CIV activities showed no difference between PwPs and controls at the group level, nor evidence of a subgroup with deficiency of either complex. There was no correlation between complex activities in platelet samples and skeletal muscle biopsies from the same individuals. Conclusions: Based on these results, we propose that platelet CI or CIV activities are not sensitive markers of mitochondrial dysfunction in PD.
- Open Access
- 10 July 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (7) , e1280
Neuronal loss drives differentially expressed protein‐pathways in the PSP globus pallidus
- 10 July 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (7) , e1280
Open AccessNeuronal loss drives differentially expressed protein‐pathways in the PSP globus pallidus
- Open Access
- 12 April 2022
- Published by Hindawi Limited in Neurology Research International
- Vol. 2022, 1-6
Use of Off-Label Drugs and Nutrition Supplements among Patients with Amyotrophic Lateral Sclerosis in Norway
Background and Objectives. Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease, characterized by gradual paralysis and muscle atrophy. Riluzole, the only approved treatment in Norway, increases mean survival by 36 months. The use of off-label medications and nutritional supplements is common in other serious conditions, such as Parkinsons disease and dementia. The aims of this study were to investigate to what extent Norwegian ALS patients use supplements and off-label medications and whether this is related to their health-related quality-of-life (HRQOL). Materials and Methods. A cross-sectional questionnaire study was performed, where 41 ALS patients reported their use of off-label treatments, as well as self-perceived HRQOL using the RAND-12 questionnaire. Results. A majority of respondents used riluzole. Of the 41 respondents, 18 (43.9) reported use of off-label medications and 18 (43.9) used nutritional supplements. Low-dose naltrexone was the most commonly used off-label medication, whereas vitamins accounted for most of the nutritional supplements. The respondents RAND-12 component scores were significantly lower than those of the general population. Low-dose naltrexone and vitamin B were associated with a better physical component score. Conclusions. Most of the respondents in our study adhere to the recommended treatment protocols, as less than half of them reported using off-label medications or nutritional supplements against ALS. Positive correlations between physical HRQOL and use of low-dose naltrexone or vitamin B were demonstrated. These results warrant further investigations.
- 12 April 2022
- Published by Hindawi Limited in Neurology Research International
- Vol. 2022, 1-6
Open AccessUse of Off-Label Drugs and Nutrition Supplements among Patients with Amyotrophic Lateral Sclerosis in Norway
Background and Objectives. Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease, characterized by gradual paralysis and muscle atrophy. Riluzole, the only approved treatment in Norway, increases mean survival by 36 months. The use of off-label medications and nutritional supplements is common in other serious conditions, such as Parkinsons disease and dementia. The aims of this study were to investigate to what extent Norwegian ALS patients use supplements and off-label medications and whether this is related to their health-related quality-of-life (HRQOL). Materials and Methods. A cross-sectional questionnaire study was performed, where 41 ALS patients reported their use of off-label treatments, as well as self-perceived HRQOL using the RAND-12 questionnaire. Results. A majority of respondents used riluzole. Of the 41 respondents, 18 (43.9) reported use of off-label medications and 18 (43.9) used nutritional supplements. Low-dose naltrexone was the most commonly used off-label medication, whereas vitamins accounted for most of the nutritional supplements. The respondents RAND-12 component scores were significantly lower than those of the general population. Low-dose naltrexone and vitamin B were associated with a better physical component score. Conclusions. Most of the respondents in our study adhere to the recommended treatment protocols, as less than half of them reported using off-label medications or nutritional supplements against ALS. Positive correlations between physical HRQOL and use of low-dose naltrexone or vitamin B were demonstrated. These results warrant further investigations.